Imagery Rescripting for Obsessive Compulsive Disorder, Body Dysmorphic Disorder and Early Psychosis: a Multiple-Baseline Single-Case Experimental Design.

Imagery Rescripting for Obsessive Compulsive Disorder, Body Dysmorphic Disorder and Early Psychosis: a Multiple-Baseline Single-Case Experimental Design. - The ImRs study for OCD, BDD and early psychosis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON53763

Enrollment

Registered

2023-07-03

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder AND Body Dysmorphic Disorder AND Psychosis

Interventions

The intervention consists of imaginary rescripting that is offered after regular intake with a variable baseline period of up to 10 weeks (OCD and BDD) and 3 weeks (psychosis) (waiting time). Patien

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Meet the criteria for OCD, BDD or psychosis, a primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed; American Psychiatric Association, 2013) • Are aged 18 and beyond • Dutch literacy • Cut-off Y-BOCS of 20 (not eligible for psychosis) • No change in medication. Stable dose at least 6 weeks prior to study (not eligible for psychosis)

Exclusion criteria

Exclusion criteria: • Current (hypo)mania • Psychotic disorder (excluding delusional symptoms related to disorder) (not eligible for psychose) • Alcohol or drugs abuse as diagnosed by DSM-5 • Electroconvulsive therapy in last 6 months • Neurological disorder or IQ

Design outcomes

Primary

Measure	Time frame
Primary outcomes - Schema or core beliefs, as measured by VAS scales. - OCD and BDD core symptoms (based on the Y-BOCS, as measured by VAS scales) - Well-being (MHQoL) and self-esteem (RSES) (Psychosis)	—

Secondary

Measure	Time frame
Secondary outcomes - Y-BOCS(-BDD), which is a semi structured interview (5 items about obsession and 5 items about compulsions). Measure: OCD and BDD symptoms. Frequency: 4 times. - Brown Assessment of Beliefs Scale (BABS), a 7-item semi-structured, rater-administered scale. Measure: Insight/delusions. Frequency: pre-post-FU - Young Schema Questionnaire (YSQ-S3) and Schema Mode Inventory (SMI), a self-report questionnaire of respectively 90 and 118 items. Measure: Schemata and modes. Frequency: pre-post-FU - Hamilton Rating Scale for Depression (HRSD), a 17-item semi-structured interview. Measure: Mood. Frequency: 4 times - VAS scales measuring core emotions (shame, guilt, anxiety, sadness, anger, disgust, repugnance). - VAS scale measuring affect strength. - VAS scale measuring obtrusiveness of imagination. - Qualitative interview and questionnaire: Imagery rescripting working mechanisms, therapeutic alliance, experiential avoidance, changes in cognition - Psychosis: PSYRATS (psychotic symptoms), trauma (PCL-5)	—

Measure

Time frame

Secondary outcomes - Y-BOCS(-BDD), which is a semi structured interview (5 items about obsession and 5 items about compulsions). Measure: OCD and BDD symptoms. Frequency: 4 times. - Brown Assessment of Beliefs Scale (BABS), a 7-item semi-structured, rater-administered scale. Measure: Insight/delusions. Frequency: pre-post-FU - Young Schema Questionnaire (YSQ-S3) and Schema Mode Inventory (SMI), a self-report questionnaire of respectively 90 and 118 items. Measure: Schemata and modes. Frequency: pre-post-FU - Hamilton Rating Scale for Depression (HRSD), a 17-item semi-structured interview. Measure: Mood. Frequency: 4 times - VAS scales measuring core emotions (shame, guilt, anxiety, sadness, anger, disgust, repugnance). - VAS scale measuring affect strength. - VAS scale measuring obtrusiveness of imagination. - Qualitative interview and questionnaire: Imagery rescripting working mechanisms, therapeutic alliance, experiential avoidance, changes in cognition - Psychosis: PSYRATS (psychotic symptoms), trauma (PCL-5)

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026